The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals
Pharmaceutics · 19.03.2025 · 17 (3) · 390
DOI: 10.3390/pharmaceutics17030390 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 19.03.2025. Verfasst von Jurga Bernatoniene und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Technology and Social Pharmacy, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, …. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 221 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Research Council of Lithuania, Research Council of Lithuania (LMTLT).
Abstract (Originalsprache)
Three-dimensional printing technology is transforming pharmaceutical manufacturing by shifting from conventional mass production to additive manufacturing, with a strong emphasis on personalized medicine. The integration of bioinks and AI-driven optimization is further enhancing this innovation, enabling drug production with precise dosages, tailored drug-release profiles, and unique multi-drug combinations that respond to individual patient needs. This advancement is significantly impacting healthcare by accelerating drug development, encouraging innovative pharmaceutical designs, and enhancing treatment efficacy. Traditional pharmaceutical manufacturing follows a one-size-fits-all approach, which often fails to meet the specific requirements of patients with unique medical conditions. In contrast, 3D printing, coupled with bioink formulations, allows for on-demand drug production, reducing dependency on large-scale manufacturing and storage. AI-powered design and process optimization further refine dosage forms, printability, and drug release mechanisms, ensuring precision and efficiency in drug manufacturing. These advancements have the potential to lower overall healthcare costs while improving patient adherence to medication regimens. This review explores the potential, challenges, and environmental benefits of 3D pharmaceutical printing, positioning it as a key driver of next-generation personalized medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Drug Technology and Social Pharmacy, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50161 Kaunas, Lithuania.
- Institute of Pharmaceutical Technologies, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50161 Kaunas, Lithuania.
ORCID-Profile: Jurga Bernatoniene, Jolita Stabrauskiene, Jurga Andreja Kazlauskaite, Dalia Marija Kopustinskiene
Förderung
- the Research Council of Lithuania
- Research Council of Lithuania (LMTLT)
Zitieren
APA
Bernatoniene, J., Stabrauskiene, J., Kazlauskaite, J. A., Bernatonyte, U., & Kopustinskiene, D. M. (2025). The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals. Pharmaceutics, 17(3), 390. https://doi.org/10.3390/pharmaceutics17030390
Vancouver
Bernatoniene J, Stabrauskiene J, Kazlauskaite JA, Bernatonyte U, Kopustinskiene DM. The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals. Pharmaceutics. 2025;17(3):390. doi:10.3390/pharmaceutics17030390
BibTeX
@article{Bernatoniene2025,
author = {Bernatoniene, Jurga and Stabrauskiene, Jolita and Kazlauskaite, Jurga Andreja and Bernatonyte, Urte and Kopustinskiene, Dalia Marija},
title = {The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {3},
pages = {390},
doi = {10.3390/pharmaceutics17030390}
}
EUVIMED